• Explore /
  • Poster
  • / Atezolizumab plus bevacizumab (A+B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network.

Atezolizumab plus bevacizumab (A+B) in patients with unresectable hepatocellular carcinoma (uHCC): Real-world experience from a US community oncology network.

Abstract Poster

Authors

null

David Cosgrove

Compass Oncology/US Oncology Network, Vancouver, WA

David Cosgrove , Amie Tan , Andrew Osterland , Sairy Hernandez , Sarika Ogale , Sami Mahrus , John Murphy , Thomas W Wilson , Gregory A. Patton , Arturo Loaiza-Bonilla , Amit G. Singal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 447)

DOI

10.1200/JCO.2024.42.3_suppl.447

Abstract #

447

Poster Bd #

A12

Abstract Disclosures

Similar Posters

First Author: Timothy J. Brown

Poster

2022 ASCO Gastrointestinal Cancers Symposium

BTCRC-GI20-457: A phase II study of atezolizumab and bevacizumab in Child-Pugh B7 hepatocellular carcinoma (the AB7 Trial).

BTCRC-GI20-457: A phase II study of atezolizumab and bevacizumab in Child-Pugh B7 hepatocellular carcinoma (the AB7 Trial).

First Author: Kristen Renee Spencer

First Author: Hirokazu Takahashi

First Author: Jay Parekh